BA
AZN icon

Bristlecone Advisors’s AstraZeneca AZN Stock Holding History

Bristlecone Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,030
Closed -$274K – 164
2015
Q4 		$274K Buy
+4,030
New +$264K 0.12% 146

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Bristlecone Advisors's AZN Position: Q1 2016 in Review

Bristlecone Advisors sold out of AstraZeneca (AZN) in Q1 2016, closing a stake of 4,030 shares — an estimated $274K sold.

Bristlecone Advisors first reported a position in AZN in Q4 2015 and held it in 1 quarter. The position peaked at $274K in Q4 2015. 390 funds tracked by Wall St. Rank hold AZN as of Q1 2016.

  • Bristlecone Advisors reported no remaining AstraZeneca position as of Q1 2016 after selling out during the quarter.
  • Bristlecone Advisors sold 4,030 AstraZeneca shares in Q1 2016, an estimated $274K.
  • Bristlecone Advisors first reported a position in AstraZeneca in Q4 2015 and held it in 1 quarter.
  • Bristlecone Advisors's AstraZeneca position peaked at $274K in Q4 2015.
  • 390 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2016.

Based on Bristlecone Advisors's 13F filing for Q1 2016, filed 10 May 2016.